Two Cancelled LOIs and a Growing Pipeline
by Kristi Marvin on 2018-04-30 at 3:29pm

Noteworthy events of the last week…

First up is Barington/Hilco with the announcement they have terminated their LOI with Specialty Brands Holdings. For those that can remember that far back, Barington/Hilco IPO’d on May 5th of 2015 and were supposed to complete a business combination in 21 months. Well, they’re going on three years now after multiple deadline extensions and are now looking at June 30th, 2018 to complete an acquisition. If they can manage to pull off yet another LOI and another extension, they could technically still complete, but realistically, how good of a transaction can they actually bring to the table with so little cash left??

Barington/Hilco still hasn’t filed their 10-K, but as of the most recent 10-Q they had only $14.7 million cash left in trust (after redemptions) and that number will likely get worse after this next round. You can see that public lack of confidence reflected in the price of the warrants which are currently trading at only $0.14….if you’re still holding the common, redeem! redeem! redeem!

Jensyn Acquisition Corp. has the exact same problem. This time however, it was the seller (BAE Energy) that terminated the LOI, but Jensyn is in a slightly better position with $41 million currently held in trust as of their recently released 10-K. Their completion deadline is June 5th, so it is highly likely they will extend.

However, both Barington/Hilco and Jensyn again demonstrate the importance of evaluating SPAC management teams and the underwriters/advisors when choosing to invest. You want an A+ SPAC management team that has solid experience negotiating deals and the ability to tap into deal flow via the banks and advisors. That’s not to say a smaller bank won’t have access to good deals (Leerink is a great example of a specialty boutique focused on the life sciences), but chances are just greater if you have a bulge bracket bank on the cover.

I’m predicting a busy summer of announcements come June and July.  There are currently 22 SPACS seeking a target that have less than one year left to complete an acquisition and of those, 11 have less than 7 months.  In order to complete by year end (and taking into account the dead month of August) you should see a flurry of annoucements in the next 2-3 months.

You can check all of the completion deadlines by checking the most recently posted weekly update found here.

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved